ISPOR ANNOUNCES CALL FOR NOMINATIONS

Published Oct 19, 2015
SUBMISSIONS BEING ACCEPTED FOR 2016-2017 BOARD OF DIRECTORS Princeton, NJ—October 19, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it is accepting nominations for the 2016-2017 Board of Directors. Board openings include President-Elect and four Director positions. As a member-driven organization, ISPOR relies on the participation of its members to fulfill the organization’s mission. Participating on the Board enables ISPOR members to lend their leadership, expertise, and vision to the discipline of health economics and outcomes research. The Board of Directors drives ISPOR’s strategic direction and is responsible for the management of the Society, including its committees, publications, budget and governance. The Board is the policy making body of the Society. Members may submit nominations on behalf of other ISPOR members or may self-nominate. Additional details on the nomination process may be found at http://www.ispor.org/board/CallForNominations-BOD2016.asp. Information on the 2015-2016 Board of Directors members (including terms of office) can be found at http://www.ispor.org/board/index.asp. The deadline for submitting nominations is January 1, 2016.

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×